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Intraoperative desorption electrospray ionization-mass spectrom-
etry (DESI-MS) is used to characterize tissue smears by comparison
with a library of DESI mass spectra of pathologically determined
tissue types. Measurements are performed in the operating room
within 3 min. These mass spectra provide direct information on
tumor infiltration into white or gray brain matter based on
N-acetylaspartate (NAA) and on membrane-derived complex lip-
ids. The mass spectra also indicate the isocitrate dehydrogenase
mutation status of the tumor via detection of 2-hydroxyglutarate,
currently assessed postoperatively on biopsied tissue using immu-
nohistochemistry. Intraoperative DESI-MS measurements made at
surgeon-defined positions enable assessment of relevant disease
state of tissue within the tumor mass and examination of the re-
section cavity walls for residual tumor. Results for 73 biopsies from
10 surgical resection cases show that DESI-MS allows detection of
glioma and estimation of high tumor cell percentage (TCP) at sur-
gical margins with 93% sensitivity and 83% specificity. TCP mea-
surements from NAA are corroborated by indirect measurements
based on lipid profiles. Notably, high percentages (>50%) of unre-
sected tumor were found in one-half of the margin biopsy smears,
even in cases where postoperative MRI suggested gross total tu-
mor resection. Unresected tumor causes recurrence and malignant
progression, as observed within a year in one case examined in this
study. These results corroborate the utility of DESI-MS in assessing
surgical margins for maximal safe tumor resection. Intraoperative
DESI-MS analysis of tissue smears, ex vivo, can be inserted into the
current surgical workflow with no alterations. The data underscore
the complexity of glioma infiltration.
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We describe the rapid analysis of neurological tissue smearsby desorption electrospray ionization-mass spectrometry
(DESI-MS) in the operating room (OR) from 10 subjects who
underwent glioma resection. Biopsied tissue specimens from
surgeon-defined positions in the tumor and the walls of the resection
cavity were smeared onto glass microscope slides and sprayed with
charged solvent droplets to extract molecules from the unprocessed
tissue while the splashed secondary droplets were vacuumed into a
customized ion-trap mass spectrometer modified for use in the OR
at Indianapolis IU (Indiana University) Health Methodist Hospital.
Three separate items of information were sought from the DESI
mass spectra: (i) tissue type, specifically whether glioma, white brain
matter, gray brain matter, or mixtures of these types; (ii) isocitrate
dehydrogenase (IDH) status, i.e., whether or not this enzyme carries
a characteristic mutation, the presence of which is associated with
more favorable prognosis; and (iii) the tumor cell percentage (TCP)
in the sampled biopsy as a measure of tumor infiltration (the latter is
arguably the most actionable intraoperatively and the one for which
the least information is currently available).
The infiltrative nature of most gliomas, as well as visual and
textural similarities between infiltrative regions and normal brain
parenchyma, poses a substantial challenge to the neurosurgeon
during tumor resection. Microsurgical resection aims to maximize
tumor excision while minimizing morbidity (1, 2) as the extent of
resection affects both overall and progression-free survival. Im-
proved survival and quality of life correlates with maximal re-
section of both low- and high-grade gliomas (3). Importantly,
tumor recurrence and malignant progression is likely to occur
from residual tumor within 0.5 cm of the resection (i.e., surgical)
margin, viz., the point at which resection ceases (3). Stereotactic
volumetric resection is usually based on preoperative structural
and functional MRI used to determine tumor location, size, sur-
gical approach, and to estimate the extent of resection achievable.
Intraoperative MRI has been implemented to mitigate anatomical
shifts and improve resection; however, MRI costs and technical
hurdles, such as prolonged surgery time for image acquisition,
limit its practical and routine implementation (1).
The standard diagnostic approach of intraoperative consulta-
tion, pathology, provides information on tumor type and grade.
Intraoperative histopathological evaluation of tissue resected from
surgical margins to estimate residual tumor infiltration is un-
common, partly because preparation and analysis of tissue sections
or smears is laborious and time-consuming, and partly due to the
inherent difficulty in assessing degree of infiltration in suboptimal
preparations. Therefore, the amount of residual tumor near the
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resection margins is not usually measured during surgery and is
only assessed postoperatively and indirectly by MRI (1, 4).
Following the publication of the 2016 WHO classification of
central nervous system tumors (5), immunohistochemistry and
molecular testing are also performed on sampled neurological
tissue to evaluate several diagnostic and prognostic markers (e.g.,
IDH mutation and 1p/19q codeletion) but results again are avail-
able only postoperatively. The need for near-real-time assessment
of tumor pathology, genetics, and margin status during surgical
resection in predicting patient outcome would suggest advantages
to a multimodal approach in which imaging and diagnostic tech-
nologies are coupled.
The analysis of neurological tissue smears using DESI-MS has
the potential to become an ex vivo diagnostic strategy that can
provide information on each of three points that we discuss in turn:
(i) Tissue type, specifically glioma, white brain matter, gray brain
matter, or a mixture of these. The use of ambient ionization MS
methods, specifically DESI (6) and rapid evaporative ionization
mass spectrometry (REIMS) (7), to distinguish diseased from
healthy tissue based on membrane-derived phospholipid signatures
is now well established. Note that an alternative method of mo-
lecular diagnosis of neurological tissue in the form of Raman
spectroscopy is being developed concurrently (8, 9). Both DESI-MS
and REIMS have been applied to different organs (7, 10–14),
generally with excellent disease discrimination via comparison with
spectra of pathology-defined reference material. REIMS requires
the use of special surgical procedures but gives real-time in-
formation. DESI gives results in a few minutes but is applicable to
any surgical method, with no alteration in procedures, and the
same tissue smears can be stained after analysis and blindly eval-
uated by an expert pathologist for validation. Whereas mass
spectral profiles (i.e., chemical signatures) of tissue sections allow
accurate differentiation between gliomas and normal brain pa-
renchyma (15–20), we emphasize in this intraoperative study the
characterization of tissue smears, especially the recognition of
those of mixed compositions. (ii) IDH status. It has previously been
shown that the presence of IDH mutation, a prognostic marker
in gliomas (21, 22), can be inferred by the MS detection of
2-hydroxyglutarate (2HG) in tissue sections (20). The same dis-
criminating information is sought here in tissue smears––which can
be prepared and analyzed inside the OR more easily and rapidly
than tissue sections (19, 23)––and this is the approach used in this
intraoperative study. (iii) Percentage of tumor cells. Encouraging
preliminary results on tissue sections indicated that it might be
possible to estimate TCP in tissue via measurements of N-acety-
laspartate (NAA). However, this highly important objective needed
to be tested in the relevant intraoperative environment, especially
on tissue resected near surgical margins for identification of re-
sidual tumor, and that is a significant aim of this study.
Results and Discussion
General Observations. Intraoperative DESI-MS was performed in
such a way as to mimic one foreseeable implementation in which a
single mass spectrometer is moved into an OR setting just before
surgery, powered on, and is ready for use within ∼30 min. The
chosen unit mass resolution linear ion-trap mass spectrometer used
(17–19) performed well without significant electronic, vacuum, or
even mass calibration problems over the 15-mo duration of the
study (SI Appendix, Table S1). Fresh tissue samples were smeared
and analyzed by DESI-MS within 3 min, a timeframe that ad-
dresses surgical needs. In the case of all surgeries, DESI-MS
analysis of multiple biopsies was completed long before any
intraoperative pathologic consultation findings were reported back
to the neurosurgeon by the neuropathologist. The observed timing
of in situ, quasi–real-time analysis by DESI-MS supports the fact
that multiple measurements––made at discrete points selected by
the neurosurgeon––are reliable and have the potential to provide
the surgeon with additional information to guide resection ma-
neuvers, particularly near critical anatomical structures.
Assessment of Disease State, TCP, and Isocitrate Dehydrogenase
Mutation Status in Tumor Cores. In current practice, biopsies
obtained from the tumor core, prepared either as frozen sections or
as smears, are evaluated by the pathologist for tumor type, grade,
and assessment of IDH mutation. Information on tumor type and
grade (i.e., low vs. high) is supplied to the neurosurgeon via tele-
phone––ideally in less than 20 min––whereas IDH assessment re-
quires more time and is only available postsurgery. Intraoperative
DESI-MS was designed to predict disease state (i.e., glioma, gray
matter, white matter, or mixed states) and TCP (i.e., TCP relative
to normal cells). The results of earlier DESI-MS studies suggested
also the ability to predict tumor grade and subtype (15). DESI-MS
predictions of disease state from tumor core margin smears were
compared with data from a library of MS spectra of known tissue
types. The comparison was made using principal component (PC1,
PC2) representations of the mass spectrum in a fashion analogous
to that used earlier for tissue sections (17). Representative data are
shown in Fig. 1. The results of these and many other such assign-
ments matched one-to-one those of pathology (Tables 1 and 2).
There are two semantic disparities (smears 27 and 28), viz., gliomas
infiltrated with ∼50% tumor cells can be logged either as glioma or
as white matter with medium TCP based on this chemical
information (SI Appendix, Table S2). Intraoperative DESI-MS
should ideally complement pathology, and the agreement be-
tween chemical and pathological diagnoses for tumor core biopsies
validates this expectation.
TCP prediction by DESI-MS supplements the disease state in-
formation. Many tumor core biopsy smears have high (>67%)
TCP, matching pathology and expectations given that high-grade
gliomas tend to be hypercellular. Exceptionally, smear 24 from
case 3 (astrocytoma WHO grade III; SI Appendix, Table S1) was
infiltrated tissue with low TCP by pathology and was predicted by
DESI-MS as white matter with 37% TCP (SI Appendix, Table S2).
SI Appendix, Fig. S1 depicts the chemical diversity of smear 24 in
Fig. 1. Chemical predictions of disease state for smears 10 (glioma, 99% TCP),
24 (white matter, 37% TCP), 40 (gray matter, 15% TCP), and 43 (glioma, 69%
TCP). Projections of the tissue smears (black objects) are imposed on the prin-
cipal component analysis (PCA) score space created from a reference DESI-MS
spectral library (17); green, gray matter; blue, white matter; red, glioma.
















comparison with another tumor core biopsy (smear 43) from a
WHO grade IV tumor with high TCP. Two smears were prepared
from nine tumor core biopsies by splitting the tissue in half. En-
couragingly, the disease state was the same and the NAA-based
predicted TCP agreed to within 15% (SI Appendix, Table S2).
IDH mutation status was assessed intraoperatively via negative-
ion DESI-MS detection of 2HG (m/z 147) followed by frag-
mentation using collision-induced dissociation for structural
confirmation. IDH mutation status is currently only determined via
immunohistochemistry and genetic testing postoperatively, even
though its intraoperative assessment could have surgical utility.
More aggressive resection of IDH-mutant tumors, which are as-
sociated with better prognosis (21, 22), significantly improves
overall and progression-free survival, whereas more aggressive re-
section of wild-type tumors does not result in such benefits (24).
The oncometabolite 2HG was detected in the tumor core biopsies
from cases 1, 3, 5, 7, and 9; these were determined postoperatively
to be IDH-mutant (SI Appendix, Table S1). In the mutant tumors,
the 2HG signal intensity varied between smears, grossly correlating
with the degree of tumor infiltration (Fig. 2), as previously ob-
served by DESI-MS for tissue sections (20). Independent studies
confirmed a positive correlation between 2HG concentration and
tumor cellularity but showed no significant differences between
tumor types and grades (24). No 2HG was detected for wild-type
tumors (SI Appendix, Fig. S2).
Assessment of Disease State and TCP at Discrete Points near
Resection Margins. Forty-four of 80 biopsies were obtained near
surgical margins (within 0.5 cm from where tumor resection ceased).
The visualization of the pseudomargin of gliomas and their margin
status can be difficult and unreliable. It is also highly unusual and
inefficient to use intraoperative pathologic consultation to de-
termine where to cease resection. Postoperative MRI normally as-
sesses the approximate volume of residual tumor. The absence of
residual contrast enhancement around the resection cavity is inter-
preted as macroscopic or gross total resection (4). We have de-
veloped two models for estimating residual tumor at discrete points
resected at the discretion of the surgeon. One is based on NAA
signal intensity whereas the other is a more indirect measure based
on the lipid profile of the tissue. Note, although we provide pre-
diction of disease state from smears of margin biopsies, the pa-
thologist does not routinely or exclusively use such samples for the
determination of tumor type, grade (such metrics are determined
using tumor core biopsies), or margin status when applicable.
N-acetylaspartate model for TCP predictions. A roughly exponential
decrease of NAA signal intensity was observed vs. pathologically
measured increase in TCP in tissue sections. This observation has
now been extended and confirmed in tissue smears analyzed intra-
operatively (SI Appendix, Fig. S3). TCP predictions based on NAA
of biopsied tissue near surgical margins ranged between 0% and
100%. Notably, about one-half of the margin tissue smears were
infiltrated with more than 50% tumor cells. Fig. 3 shows the fre-
quency of low, medium, and high TCP, as well as of the disease state
predictions, both compared with histopathological results. Agree-
ment is good. The absence of a signal for NAA in tissue––when a
distinct glioma lipid profile is present––is specific for high-density
gliomas (SI Appendix, Table S3). Sensitivity is also high, as just three
smears (69, 77–79) showed low NAA signal (TCP estimates between
73–74%; SI Appendix, Table S2) when pathology determined less
than 10% tumor cells. The presence of vascular proliferation was
noted in these smears. The availability of an intraoperative tool for
identification of high (>50%) residual tumor infiltration at surgical
margins is essential for neurosurgeons to refine surgical maneuvers.
Safe removal of high tumor infiltration is a primary goal of neuro-
surgery whereas areas of low infiltration are more likely the target of
coadjuvant postsurgical therapies. Our current qualitative method-
ology is less accurate in differentiating betweenmedium and low TCP
(SI Appendix, Table S3). The literature suggests that NAA varies with
age, gender, and other biological factors (25) that were not controlled
in this small study. Biological variability affecting agreement between
chemical and pathological estimations manifests itself when NAA is
present in the tissue; i.e., in low- and medium-infiltrated tissue.
Lipid profile deconvolution for evaluation of tumor density. The lipid
profile detected by DESI-MS can show the presence of tumor in
tissue and distinguishes the background into which the tumor in-
filtrates; i.e., gray or white brain matter (17). The dynamic changes
of DESI-MS lipid profiles acquired from tissue sections were
previously interpreted in terms of three-component mixtures of
glioma, white matter, and gray matter (SI Appendix, Fig. S4). The
dynamics are reflective of the infiltrative nature of gliomas into the
surrounding brain parenchyma. A linear regression model was
developed to determine composition of gray matter, white matter,
and glioma based on a reference spectral library (see details in SI
Appendix). We further speculate that the deconvolution of lipid
profiles into fractions of white matter, gray matter, and glioma can
indicate tumor density and corroborate NAA predictions. In the
44 margin smears analyzed, the lipid deconvolution underscored
the complexity of gliomas identifying tumor infiltration into white-
(e.g., smear 18) or gray matter (e.g., smear 44), into a mixture of
those (e.g., smear 49), or even identifying mixtures of gray and
white matter with no detectable presence of tumor cells (e.g.,
smear 68). SI Appendix, Fig. S5 depicts the dynamic of the lipid
profiles reflecting such complexity. This determination is made
even more difficult during pathological evaluation by the fact that
tumor effaces normal parenchyma resulting in identification of
infiltrated tissue (not otherwise specified) [(IT nos); Fig. 3]. Most
tumors infiltrate into white matter, so their lipid signatures express
high abundances of sulfatides related to myelination of neurons
(17). Only a few smears showed infiltration into gray matter
(smears 20, 26, 40, 42, 44, 45, 55, 67, and 68; SI Appendix, Table
S2). In these cases, pathological evaluation confirmed the presence
of gray matter infiltrated with tumor cells or mixed with white
matter. As was the case for NAA, tissue near surgical margins
showed high heterogeneity in lipid expression. The deconvolution
of lipid profiles of the smears into their constituent tissue types
accurately identified low- (14 smears of 18) and high-density gli-
omas (10 smears of 14), whereas less accuracy was obtained for
medium-infiltrated tissue (SI Appendix, Table S4). A larger cohort
of patients is necessary to develop a more accurate multifactorial
regression model based on experimental results rather than using
the assumption of linear combination with no interactions.
Residual tumor near surgical margins. Tumor infiltration varied
greatly not only in biopsied tissue resected near surgical mar-
gins but also within the epicenter of the tumor. The peculiar
Table 2. Association between chemical predictions of
TCP vs. pathology for tumor cores
Chemical evaluation of tumor cell percentage
Pathological evaluation Low (<33%) Medium (34–67%) High (>67%)
Low 0 2 2
Medium 0 2 1
High 0 0 21
Table 1. Association between chemical predictions of disease
state and pathology for tumor cores
Chemical evaluation of disease state
Pathological evaluation Gray matter White matter Glioma
Infiltrated tissue 0 3 1
Glioma 0 2 22
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behavior of gliomas to infiltrate irregularly into brain matter,
mostly following white-matter tracts, was observed in the mul-
tiple measurements performed by DESI-MS. We found high
TCP near the margins in both high- and low-grade gliomas,
with only a weak relationship between TCP and biopsy location
within the tumor volume (i.e., decreasing TCP moving from
tumor core to margins). Marginal points sometimes showed
TCP higher than those measured inside the tumor. As extreme
examples, we detail cases 2 and 4. For case 4, glioblastoma
WHO grade IV, two biopsies (smears 25 and 26) obtained near
surgical margins had TCP (predicted using NAA) of 75% and
0%, respectively, matching pathology (high and low TCP). Two
biopsies resected inside the tumor mass showed TCP of about
40% (SI Appendix, Table S2). For case 2, dysembryoplastic
neuroepithelial tumor WHO grade I, discrete biopsied tissue
resected near the surgical margins showed TCP from 65% to
93% (Fig. 4). Again, marginal points showed TCP higher than
discrete locations inside the tumor mass (SI Appendix, Table
S2). Similar trends were found in the other cases as well (SI
Appendix, Table S2). Remarkably, and unfortunately, post-
operative MRI provided no evidence of residual tumor in any
of the cases except 1 and 2. Limitations in estimating extent of
resection by MRI exist and are largely due to lack of correlation
between MRI contrast enhancement and histological compo-
sition of the tissue, difficulties in calculating tumor volume, and
the occurrence of nonenhancing tumors (4). Also, the volume
of the resection cavity does not provide a true indication of the
residual microscopic tumor burden (3). Unresected tumor is
the primary cause of recurrence and malignant progression.
This is shown in cases 1 and 7, which refer to the same subject
who underwent glioma resection twice within one year. The
primary tumor was diagnosed as oligodendroglioma WHO
grade II, using WHO 2007 terminology (SI Appendix, Table
S1). The tumor was adherent to medial structures and the
lateral thalamus; only partial tumor resection was performed as
total resection was determined to be unsafe. Residual tumor
was detected by DESI-MS in the posterior margin, with TCP
ranging between 74% and 88% into the biopsied tissue (smears
6–8, case 1). A secondary tumor mass recurred from the pos-
terior margin and progressed into glioblastoma WHO grade IV
(SI Appendix, Fig. S6). Notably, the lipid signature of the re-
current tumor showed higher intensity of phosphatidylinositol
(38:4), m/z 885.5 (SI Appendix, Fig. S6), which has been noted
as a discriminatory marker for glioblastoma in previous DESI-MS
studies (15). Also, DESI-MS identified the presence of 2HG in the
primary oligodendroglioma, indicative of IDHmutation, confirmed
postoperatively (SI Appendix, Table S1). Progression of oligo-
dendrogliomas into glioblastomas occurs predominantly in
IDH-mutant tissue (21, 22).
Conclusions
Rapid DESI-MS analysis of tissue smears was performed inside the
OR during glioma resection. The results from the first 10 patients
in a projected 50-patient study indicate that the DESI-MS meth-
odology is simple, reliable, and can be inserted into the current
surgical workflow without interference. Simplicity of the in-
strumentation, a low-resolution ion-trap mass spectrometer, and
the methodology is desirable for robustness and ruggedness. DESI-
MS faithfully recapitulates basic diagnostic information (disease
state and TCP) in less time than is needed for pathological eval-
uation. This enables multiple direct measurements on neurological
tissue for examination of clinically relevant variants within the tu-
mor and for the assessment of discrete points in the resection cavity
for residual tumor. The finding that biopsies taken near each other
and having similar tumor types can show vastly different TCPs
speaks to the complexity and known heterogeneity of glioma in-
vasion into adjacent tissue. This heterogeneity partly accounts for
failure of single treatment paradigms. High percentages of tumor
cells were found near surgical margins, even in cases where post-
operative MRI showed gross total resection, corroborating the
utility of DESI-MS coupled with neuronavigation to assist in
maximal tumor resection, an outcome associated with better pa-
tient survival. In situations where tumor is detected but cannot be
safely removed, intraoperative measurement of residual tumor can
Fig. 3. Margin smears (n = 44). (A) Frequency of DESI-MS prediction of disease state vs. pathology. G, glioma; GM, gray matter; IT (nos), infiltrated tissue (not
otherwise specified); WM, white matter. DESI-MS has no IT (nos) assignments because all smears were assigned. (B) Frequency of DESI-MS prediction of TCP using
NAA vs. pathology. Percentages of tumor cells are categorized as low (<33%), medium (34–67%), and high (>67%).
Fig. 2. Signal intensity of 2HG (m/z 147) normalized to the total ion counts in
smears 62–70 for case 9. Secondary axis shows TCP as estimated by pathology
in the same smears.
















serve to focus the delivery of adjuvant postsurgical therapies.
Intraoperative DESI-MS can assess the presence of IDH mutation
via detection of 2HG. Intraoperative assessment of IDH mutation
could differentiate low-grade glioma from reactive tissue, poten-
tially influencing surgical decision-making process and aggressive-
ness of resection, predominantly based on tumor location (24). The
DESI-MS methodology can be improved to become more quan-
titative and relevant for detection of important markers such as
2HG and NAA. Prospective randomized clinical trials will be
necessary to further validate these results and define how DESI-
MS can be used to expedite clinical decision-making and improve
the care of brain tumor patients.
Fig. 4. Chemical predictions of disease state and tumor cell percentage. (A) Three-dimensional mapping of chemical predictions over MRI volume reconstruction
for case 4 with overlaid stereotactic positions of smears 25–29. Stereotactic positions were registered digitally to the preoperative MRI using neuronavigation in
the OR. Stereotactic positions are color coded by classification using PCA and linear discriminant analysis: green, gray matter; blue, white matter; red, glioma. (B)
TCP predictions via linear regression using NAA for smears 25–29. Gray objects, natural log of the NAA signal intensity (normalized to the total ion count) vs. TCP
for histologically defined reference specimens with a line of regression (black line); red objects, predictions of tissue smears. The equation of the regression line was
calculated as y = –0.03x + 0.59 with a Pearson correlation r of –0.89. (C) Three-dimensional mapping of chemical predictions overMRI volume reconstruction for case
2 with overlaid stereotactic positions of smears 12–17. The stereotactic image for the biopsied tissue corresponding to smears 10 and 11 was not recorded. (D) TCP
predictions via linear regression using NAA for smears 10–17.
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Materials and Methods
Ten subjects who underwent glioma resection were recruited in this study
[Indiana University Institutional Review Board (IRB) Protocol No. 1410342262].
The Health Insurance Portability and Accountability Act authorization was
obtained from each subject. Details on the patient cohort are reported in SI
Appendix, Table S1. Tissue biopsies (total of 73 smears; SI Appendix, Table S2)
collected from stereotactically registered positions in either the tumor core or
near the surgical margins (within 0.5 cm from where tumor resection ceased)
were obtained during surgical glioma resection and analyzed using DESI-MS in
the OR. The number and size of the biopsies were determined at the discretion
of the neurosurgeon. Tissue specimens (5–50 mm3) were smeared on standard
microscope glass slides (18). The act of smearing homogenizes the tissue and
allows acquisition of representative data even when examining a small fraction
of the surface of the smear, thereby limiting the analysis time to a few minutes
(19, 23). Scans acquired orthogonally to the smearing direction average any
remaining heterogeneity of the tissue, a conclusion which is supported by DESI-
MS images of tissue smears (SI Appendix, Fig. S7). DESI-MS was performed using
dimethylformamide-acetonitrile (1:1 vol/vol), a solvent that preserves tissue
morphology (26). MS measurements were performed using a linear ion-trap
mass spectrometer (Finnigan LTQ, Thermo Scientific) modified for use in the
OR; details in SI Appendix. Smears were subjected to sequential negative-
mode DESI-MS (analysis time, 2.2 min) to obtain spectral signatures providing
information on the presence of tumor, the extent of tumor infiltration, and the
presence of IDH mutation via 2HG detection. The same smears analyzed by
DESI-MS were stained and blindly evaluated by an expert neuropathologist,
postoperatively, to provide information on overall diagnosis, TCP, and WHO
grading when feasible. Chemical data were analyzed offline to minimize the
potential influence on surgical decision-making (following the terms of ap-
proved IRB); computations are rapid, simple, and feasible in situ. Smears were
diagnosed as gray brain matter, white brain matter, or glioma via pattern
recognition of their DESI-MS spectral signatures using a reference DESI-MS
spectral library (17). Additional information can be found in SI Appendix.
TCP was predicted using the relative intensity of NAA (17) as well as from the
lipid profiles. Preoperative and postoperative MRI scans, radiology, operative,
and pathology reports were obtained for each case within 2 wk of surgery.
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